thrombopoietin receptor agonists
Treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a procedure.
Acts as a thrombopoietin receptor agonist which increases platelet production by initiating proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.
Distribution: Well distributed to tissues.
Protein Binding: >99%.
Metabolism and Excretion: Primarily metabolized in liver via CYP4 isoenzymes. Primarily excreted in feces (83%) with 16% being eliminated as unchanged drug.
Half-life: 27 hr.
TIME/ACTION PROFILE (plasma concentrations)
|PO||unknown||6–8 hr||24 hr|
Use Cautiously in:
GI: PORTAL VEIN THROMBOSIS
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Should not be used in patients with chronic liver disease to normalize platelet counts.
PO (Adults): 3 mg once daily for 7 days. Begin therapy 8–14 days prior to the scheduled procedure such that the procedure takes place 2–8 days after the final dose.
Tablets: 3 mg
Lab Test Considerations:
Obtain platelet count before starting therapy and not >2 days before procedure.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. Complete Product Information.